Molecular therapy for Metastatic cancers: Ivermectin, the anthelmintic drug, increases the expression of tumor suppressors RECK1 and CADM1, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 30/August/2017, 12.50 am

Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients: A pharmaceutical mixture encompassing Ajoene and Cardamonin (AC) increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene, 30/August/2017, 12.33 am
August 29, 2017
Natural product-derived  therapy for enhancing anti-cancer immunity: Dihydroartemisinin (DHA), a derivative of Artemisinin isolated from Artemesia anuua L, decreases the level of LATS1/2 (large tumor suppressor 1 and 2), increases immunogenicity of tumors, enhances anti-tumor immune responses, and inhibits tumor growth via down regulation of its target gene, 30/August/2017, 1.26 am
August 29, 2017
Show all

From Significance of the study to Public health relevance:

Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them will die; (ii) cancer deaths globally are expected to be doubled by 2030; (iii) most of the cancer patients die due to metastasis; (iv) cancer treatment causes the highest economic loss compared to all the known causes of death worldwide, there is an urgent need to find: (i) bio-molecules that drive metastatic process; and the the way to prevent their expression; (ii) a way to activate immune system to combat cancer (Cancer immunotherapy); (ii) a cheaper alternative to the existing expensive anticancer drugs; (ii) a side-effect-free natural product-based drug; (iii) increase the therapeutic index of anticancer drugs; and (iv) a way to effectively treat and prevent metastatic progression and relapse of advanced/drug-resistant cancers.


Research findings to Therapeutic opportunity: 

A number of studies suggests that Ivermectin  inhibits tumor cell proliferation. However, the mechanism of action is far from clear.

This study suggests that Ivermectin, by regulating the expression of its target genes, it may increase the expression of tumor suppressors RECK1 and CADM1 (fig. 1).

[easy_payment currency=”USD”]

Thereby, it may: (a) inhibit cell cycle progression; and (d) suppress migration, invasion and metastasis of cancer cells. 

Thus,  Ivermectin-based treatment may be advised for metastatic cancer patients to (i) increase the expression of tumor suppressor/DNA repair genes in tumors; (ii) inhibit the progression of metastatic tumors; and (ii) enhance the efficacy of Cancer therapy. Together, oncologists may consider experimenting Ivermectin in the treatment of advanced metastatic cancers.


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $10#

Undisclosed mechanistic information: How Ivermectin increases the expression of tumor suppressors RECK1 and CADM1

Fig1. Mechanistic insights into the anthelmintic drug Ivermectin functions as an anti-metastasis agent. Ivermectin increases the expression of  tumor suppressors RECK1 and CADM1  via down regulation of its target genes.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

For purchase and payment details, you may reach us at info@genomediscovery.org

# Research cooperation


References: 

CitationBoominathan, L., Molecular therapy for Metastatic cancers: Ivermectin, the anthelmintic drug, increases the expression of tumor suppressors RECK1 and CADM1, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 30/August/2017, 12.51 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or newbioideas.com/

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.